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Abstract 
The aim of this study was to evaluate the effects of the mitogen-activated protein kinase (MAPK) pathway 
inhibitors SB203580, CMPD-1, SB239063, SP600125, and FR180204 on the activity of P-glycoprotein (P-gp) 
and to assess whether the MAPK pathway affects P-gp directly. Changes in the fluorescence of residual 
rhodamine 123, a marker of P-gp activity, in the apical region of Caco-2 cells were measured in the 
presence of MAPK pathway inhibitors using time-lapse confocal laser scanning microscopy at 0, 10, 20, 30, 
and 60 min. Significant differences were observed between the fluorescence levels of control cells and cells 
treated with SB203580 for 20, 30, or 60 min. However, no significant change was observed in the residual 
rhodamine 123 fluorescence of cells treated with CMPD-1, SB239063, SP600125, or FR180204. Among the 
p38-MAPK pathway inhibitors investigated, CMPD-1 and SB239063 showed no detectable effect on the 
activity of P-gp. Further, JNK 1, 2, 3-MAPK pathway (SP600125) and ERK1/2 pathway (FR180204) 
inhibitors did not affect P-gp activity. However, SB203580 enhanced the transfer of rhodamine 123 across 
the apical cell membrane. Thus, SB203580 activated P-gp, although not through the p38-MAPK pathway. 
Importantly, the MAPK pathway did not affect P-gp activity shortly after treatment. 
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Introduction 
P-glycoprotein (P-gp) is the most thoroughly studied member of the adenosine triphosphate-binding 
cassette transporter superfamily and is expressed throughout the intestinal epithelium, hepatocytes, renal 
tubular cells, and the blood-brain barrier [1]. P-gp is encoded by the ABCB1/MDR1 gene in humans [2]. 
Because of its ubiquitous expression and broad specificity, changes in P-gp expression or efflux activity 
induced by drug treatments, diet, environmental factors, or single nucleotide polymorphisms (SNPs) can 
greatly affect drug disposition, pharmacokinetics, and clinical response [3]. Hence, identification of P-gp  
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Figure 1.  The MAPK pathway 
substrates is important for therapeutic optimization and to avoid drug-drug interactions. However, little is 
known of P-gp regulation. 
Mitogen-activated protein kinases (MAPKs) are a family of Ser/Thr protein kinases that are widely 
conserved among eukaryotes and are involved in many cellular functions. The p38-MAPK and c-Jun N-
terminal kinase (JNK)-MAPK signalling pathways allow cells to interpret a wide range of external signals and 
respond appropriately by generating a plethora of different biological effects. There are four p38 subtypes 
(p38α, p38β, p38γ, p38δ) and three JNK subtypes (JNK1, JNK2, JNK3) [4,5]. The extracellular signal-
regulated kinase (Erk1/2)-MAPK signalling pathway can be activated in response to a diverse range of 
extracellular stimuli, including mitogens, growth factors, and cytokines (Fig. 1) [6]. Several studies have 
indicated that MAPK signalling pathways may regulate membrane trafficking proteins. For example, 
Fujishiro et al. reported that activation of the p38-MAPK pathway is not necessary for insulin-induced 
glucose uptake but that it regulates glucose transporter expression [7]. Nagelin et al. reported that murine 
12/15-lipoxygenase regulates the expression and function of the ATP-binding cassette transporter G1 
through p38- and JNK2-dependent pathways [8]. These reports suggest that the MAPK pathway transmits 
signals to membrane trafficking proteins to regulate their activity. 
In the present study, we evaluated the effects of MAPK pathway inhibitors (SB203580, competitive 
p38α and β inhibitor; CMPD-1, non-competitive p38α inhibitor; SB239063, competitive p38α and β specific 
inhibitor; SP600125, competitive JNK 1, 2, 3 inhibitor; FR180204, competitive ERK1/2 inhibitor) on the 
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activity of P-gp using time-lapse confocal laser scanning microscopy. The confocal laser scanning 
microscopy-based assay was used to measure residual rhodamine 123 in the apical region of Caco-2 cells; 





SB203580 was obtained from InvivoGen (San Diego, CA, U.S.A.). CMPD-1 was obtained from Tocris 
Bioscience (Ellisville, MO, U.S.A.). SB239063 was obtained from Sigma-Aldrich (St. Louis, MO, U.S.A.). 
SP600125 was obtained from Cayman Chemical (Ann Arbor, MI, U.S.A.). FR180204 was obtained from 
Santa Cruz Biotechnology (Santa Cruz, CA, U.S.A.). Rhodamine 123 was obtained from Molecular Probes 
(Eugene, OR, U.S.A.). 
 
Cell culture of Caco-2 cells 
The human colon adenocarcinoma cell line (Caco-2) was purchased from DS Pharma Biomedical (Osaka, 
Japan). The cells were used for experiments 7 d after seeding and between passages 47 and 52. 
 
Figure 2.  The protocol for measurement of P-glycoprotein-mediated transport activity using confocal laser-scanning 
microscopy in the presence or absence of inhibitor agents. 
 
Quantification of rhodamine 123 by time-lapse confocal laser scanning microscopy 
Transport measurements were performed in a transwell chamber (BD Biosciences, San Jose, CA, U.S.A.). 
Caco-2 cells were seeded at a density of 3 × 104 cells per filter on polyethylene terephthalate filters in the 
cell culture inserts. 
The cell culture inserts were placed on a glass-bottomed dish, and the Caco-2 cells were incubated with 
5 µM rhodamine 123 for 90 min at 37°C. The cells were rinsed with Hanks’ Balanced Salt Solution (HBSS). 
HBSS with or without MAPK pathway inhibitors was added to the cells (SB203580, 10 µM; CMPD-1, 10 µM; 
SB239063, 100 nM; SP600125, 100 nM; FR180204, 1 µM), and cells were observed by time-lapse confocal 
laser scanning microscopy (Fig. 2). Quantification of the intracellular concentration of rhodamine 123 in the 
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Caco-2 cells was performed using fluorescent images at several time points (0, 10, 20, 30, and 60 min) by a 
chronological measurement program (EZ-C1; Nikon, Tokyo, Japan). The fluorescence intensity at 0 min was 
defined as 100 % [9,10]. 
 
Statistical analysis 
All values represent the mean ± standard error. The data were analysed using a two-way ANOVA 
followed by a Bonferroni post-test to determine significance (P < 0.05). Statistical analyses were performed 
using the GraphPad Prism 4.03 software (GraphPad Software, La Jolla, CA, U.S.A.). 
 
Results and Discussion 
The level of residual rhodamine 123 fluorescence in control cells and cells treated with MAPK pathway 
inhibitors were measured with time-lapse confocal laser scanning microscopy to assess P-gp activity. 
Treatment with 10 μM SB203580, a competitive inhibitor of the p38α and β ATP binding pocket, enhanced 
the fluorescent decrease significantly at 20, 30, and 60 min (Fig. 3a). In contrast, the decrease in 
fluorescent intensity was not affected by treatment with the JNK 1, 2, 3 inhibitor, SP600125 (100 nM), or 
the ERK1/2 inhibitor FR180204 (1 μM) (Fig. 3b, c). Further, the decrease in fluorescent intensity was not 
affected by the non-competitive p38α inhibitor CMPD-1 (10 μM) (Fig. 3d) or a second, more specific 
competitive inhibitor of the p38α and β ATP binding pocket, SB239063 (100 nM) (Fig. 3e).  
We evaluated the effects of MAPK pathway inhibitors on the activity of P-gp, using time-lapse confocal 
laser scanning microscopy. SB203580 enhanced the fluorescent decrease significantly after 20 min. It is 
hypothesized that the enhanced effect of SB203580 is due to changes in P-gp activation, as changes to the 
P-gp expression level would require at least 24 h of drug treatment. SB203580 is a pyridinyl imidazole that 
competitively inhibits ATP binding and is widely used in studies for elucidating the roles of p38-MAPK [11]. 
Barancík et al. reported that treatment of the multidrug resistant mouse leukaemia cell line L1210/VCR 
with SB203580 (30 µM) for 3 days inhibited P-gp [12]. In contrast, our results suggest that treatment of the 
human colon adenocarcinoma cell line Caco-2 with SB203580 (10 µM) for 60 min activates P-gp. The 
difference in effect may be due to differences in cell lines, SB203580 concentration, and duration of 
treatment. 
Furthermore, the decrease in fluorescent intensity was not affected by SP600125 and FR180204. 
SP600125 is a JNK 1, 2, 3 inhibitor and FR180204 is an ERK1/2 inhibitor. Our results suggest that the JNK-
MAPK and ERK1/2-MAPK pathways do not affect P-gp activity directly or over the time course studied. 
Supporting our data, Kim et al. have also reported that SP600125 had no effect on P-gp [13]. 
The enhancement of P-gp activity following SB203580 treatment suggested that activation of the p38-
MAPK pathway might inhibit P-gp. As mentioned earlier, SB203580 competitively inhibits ATP binding to 
p38 α and β. Further, P-gp is an ATP-dependent transporter. Thus, we hypothesized that inhibition of ATP 
binding to p38α and β by SB203580 might enhance available ATP levels, thereby enhancing the activation 
of P-gp. To further assess the contribution of p38-MAPK pathways, cells were treated with either CMPD-1 
or SB239063. CMPD-1 is a selective, non-competitive inhibitor of p38α, and SB239063 is a competitive 
inhibitor of p38-MAPK [14,15]. Importantly, SB239063 is more specific than SB203580 [15]. Interestingly, 
both CMPD-1 and SB239063 had no detectable effect on the activity of P-gp. Thus, our results suggest that 
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the p38-MAPK pathway does not affect P-gp directly after a short duration of treatment. However, 
SB203580 increased the transfer of rhodamine 123 across the cell membrane after 20 min. 
 
Figure 3.  Influence of MAPK pathway inhibitors on the time-dependent decrease in residual rhodamine 123 
fluorescence in the apical region of Caco-2 cells, measured by time-lapse confocal laser scanning microscopy. Each 
chamber represents a p38-MAPK pathway inhibitor: (a) SB203580, 10 µM: (b) SP600125, 100 nM; (c) FR180204, 1 µM: 
(d) CMPD-1, 10 µM: (e) SB239063, 100 nM. Each point and bar represents the mean ± standard error. n = 12-18.
 *,***
 
Significant difference between the control group and SB203580 group (P < 0.05, 0.001). 
 
There are two possible reasons for the enhanced rhodamine transport. Firstly, the effect of SB203580 
could be mediated through pathways other than the p38-MAPK pathway. The working concentration of 
SB203580 reported in the literature is 1-20 µM. However, at high concentrations, SB203580 can also affect 
Raf-1, phosphoinositide-dependent protein kinase 1 (PDK1), the transforming growth factor-beta (TGF-β) 
receptor, cyclooxygenase 1 (COX-1), and cyclooxygenase 2 (COX-2) [16]. Additionally, Lali et al. reported 
that low concentrations of SB203580 can inhibit the phosphorylation and activation of protein kinase B 
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(PKB), also known as Akt, by inhibiting the PKB kinase, PDK1 (IC50, 3-5 µM) [17]. It is possible that the 
activation of P-gp by SB203580 may occur via one of these pathways. Alternatively, SB203580 could cause 
a structural change in P-gp. P-gp is one of the best-characterized ABC transporters; however, the 
mechanism of substrate transport is unclear. In particular, it has been hypothesized that there are many 
possible drug-binding sites on P-gp, including up to seven putative binding sites located in the 
transmembrane domain of the protein [18-20]. It is generally accepted that transmembrane helices 5, 6, 
11, and 12 are involved in P-gp substrate binding. One popular model published by Shapiro et al. suggested 
that two different functional binding sites, the R-site and H-site, interact in a positive cooperative 
manner.18 Rhodamine 123 and anthracylines are substrates of the R-site, whereas colchicine is a substrate 
of the H-site of P-gp. This two-site hypothesis is the most convenient working model that explains the 
mutual stimulation of P-gp-mediated transport by several substrates. Additionally, there is evidence of a 
third allosteric binding site that serves a regulatory function and may be the site of progesterone binding 
[21]. Sterz et al. reported that some substances are activators of P-gp [22]. Further, Kerboeuf et al. 
reported that macrocyclic lactone anthelmintics activate P-gp in nematodes and suggested that several 
substituents in the macrocyclic lactone structure are involved in modulating P-gp activation [23]. 
 
Conclusions 
The MAPK pathway does not affect short-term P-gp activation. Rather, activation of P-gp by SB203580 
is likely due to either pathways other than the p38-MAPK pathway or allosteric structural changes in P-gp. 
Thus, further studies should be performed to understand the mechanism underlying SB203580-mediated 
P-gp activation. 
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